Plasminogen activator inhibitor 1 activity and lipoprotein(a) in nephropathic patients with non-insulin-dependent diabetes mellitus versus patients with nondiabetic nephropathy.
Increased plasma activity of plasminogen activator inhibitor 1 (PAI-1) is considered as a risk factor for thrombosis associated with atherosclerosis by reduction of fibrinolysis. Since nephropathic patients with non-insulin-dependent diabetes mellitus (NIDDM) are a cardiovascular high-risk group, which has yielded only controversial results as to the regulation of PAI-1, we compared 19 overt nephropathic NIDDM patients (mean age 63 years, serum creatinine 1.9 mg/dl, proteinuria 4.2 g/day) to 17 nondiabetic nephropathic patients with various causes of renal insufficiency (mean age 63 years, serum creatinine 2.8 mg/dl, proteinuria 3.9 g/day). We found normal PAI-1 levels for patients with diabetic nephropathy and significantly elevated PAI-1 levels within the upper normal range for nondiabetic nephropathic patients. Common risk factors in both groups were very high levels of fibrinogen, lipoprotein(a), serum cholesterol, and LDL cholesterol.
Medical Department A, Hospital Ludwigshafen, FRG.
T
T
Schleiffer
P
P
Hellstern
M
M
Freitag
H
H
Brass
D000990:Antithrombin III / Q000032:analysis; D002318:Cardiovascular Diseases / Q000453:epidemiology; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D003928:Diabetic Nephropathies / Q000097:blood*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D007674:Kidney Diseases / Q000097:blood*; D017270:Lipoprotein(a) / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis*; D011486:Protein C / Q000032:analysis; D011507:Proteinuria / Q000209:etiology; D012307:Risk Factors
D017270:Lipoprotein(a); D017395:Plasminogen Activator Inhibitor 1; D011486:Protein C; D000990:Antithrombin III; D005340:Fibrinogen; D002784:Cholesterol